A Test of MDMA-Assisted Psychotherapy in People With Posttraumatic Stress Disorder

Randomised, triple-blind, placebo-controlled trial comparing MDMA-assisted psychotherapy with psychotherapy plus inactive placebo in adults with chronic, treatment-resistant PTSD, including veterans.

Participants received two blinded 8-hour sessions (125 mg oral MDMA with a 62.5 mg supplemental dose, or matched placebo), with preparatory and integration therapy. Primary outcome: change in CAPS-IV two months post-treatment.